<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887858</url>
  </required_header>
  <id_info>
    <org_study_id>BE117711819/DDS18-029BE</org_study_id>
    <nct_id>NCT03887858</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. &quot;Harnal-D&quot; in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical &quot;Chong Kun Dang Tamsulosin HCl Tablet&quot; and Astellas Phama Korea Inc. &quot;Harnal-D&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, fasted, single dose, crossover study to evaluate the
      bioequivalence of Chong Kun Dang Pharmaceutical &quot;Chong Kun Dang Tamsulosin HCl Tablet&quot; and
      Astellas Phama Korea Inc. &quot;Harnal-D&quot; in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of thirty (30), following treatments are administered dosing in each
      period and wash-out period is a minimum of 1 week.

      Reference drug: Harnal-D Tab. / Test drug: Chong Kun Dang Tamsulosin HCl Tab. Pharmacokinetic
      blood samples are collected up to 48hrs. The pharmacokinetic characteristics and safety are
      assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2019</start_date>
  <completion_date type="Actual">May 7, 2019</completion_date>
  <primary_completion_date type="Actual">March 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of Chong Kun Dang Tamsulosin HCl Tablet and Harnal-D</measure>
    <time_frame>Pre-dose (0 hour), post-dose 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>Area under the Chong Kun Dang Tamsulosin HCl Tablet / Harnal-D concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Chong Kun Dang Tamsulosin HCl Tablet and Harnal-D</measure>
    <time_frame>Pre-dose (0 hour), post-dose 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48 hours</time_frame>
    <description>The maximum Chong Kun Dang Tamsulosin HCl Tablet / Harnal-D concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Reference/Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Harnal-D Tab. 1T
Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test/Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T
Period 2: Harnal-D Tab. 1T</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Harnal-D Tab.</intervention_name>
    <description>Harnal-D Tab. 1T single oral administration under fasting</description>
    <arm_group_label>Reference/Test</arm_group_label>
    <arm_group_label>Test/Reference</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chong Kun Dang Tamsulosin HCl Tab.</intervention_name>
    <description>Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition</description>
    <arm_group_label>Reference/Test</arm_group_label>
    <arm_group_label>Test/Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy subject older than 19 years men at the screening

          2. Individuals without congenital/chronic diseases and without abnormal symptoms or
             diagnosis based on a medical examination(if necessary, EEG, ECG, chest X-ray,
             endoscope or upper gastrointestinal radiography)

          3. Individuals who were deemed to be appropriate as study subjects in accordance with the
             screening results (laboratory tests, ECG etc.)

          4. Individuals who had 18 kg/m2 ≤ Body Mass Index(BMI) ≤ 30kg/m2

             * BMI = Weight(kg)/ Height(m)2

          5. Individuals who had agreed to participate in the study

          6. Individuals without mental illness history within five year prior to the screening

          7. Individuals without a medical history of gastrointestinal operations that may affect
             drug absorption

          8. Individuals who do not agree to the approved methods of double contraception and using
             spermicide for up to 7 days after investigational product(s) administration

        Exclusion Criteria:

          1. Individuals who had enrolled to barbiturate's drugs by induction and inhibition of
             drug-metabolizing enzymes of drugs within the 1 month

          2. Individuals who had excessive drinking within the 1 month

             *Men: 21 glasses/week exceeded(1 glass: distilled spirits 45 mL, wine 150 mL, beer 360
             mL)

          3. Individuals who had taken any medication within 10 days prior to the first day of
             dosing

          4. Individuals who were deemed to be inappropriate to participate in the study by the
             investigator

          5. Individuals who had participated of other clinical study or bioequivalence study
             within the 3 months prior to the first day of dosing

          6. Individuals who donated whole blood within the 2 months, or blood components within 1
             weeks prior to the first dose of the investigational product(s)

          7. Individuals with hypersensitivity (include Vascular edema) to ingredients used in the
             investigational product(s)

          8. Individuals with hereditary diseases of galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption etc.

          9. Individuals with orthostatic hypotension

         10. Individuals with severe hepatopathy

         11. Individuals who had taken alpha-1 blocker

         12. Individuals who had history of micturition syncope

         13. Individuals with nephropathy

         14. Elderly person

         15. Individuals who had taken PDE5(phosphodiesterase-5) inhibitor

         16. Individuals who had taken CYP3A4 inhibitor

         17. Individuals who had taken antihypertensive drug(s)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Jung Cha</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bestian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bestian Hospital</name>
      <address>
        <city>Osong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

